CS Analytical Laboratory, the world's only cGMP, FDA-registered and inspected contract laboratory exclusively designed and ...

Orchestra BioMed (NASDAQ:OBIO – Get Free Report) will likely be issuing its quarterly earnings data before the market opens ...

Key takeaways Projected return on investment in pharma research and development (R&D) in 2024 has risen to 5.9%, continuing the upward trajectory from 2023's 4.1%.GLP-1 therapies have played a ...

BTIG Research initiated coverage on shares of Orchestra BioMed (NASDAQ:OBIO – Free Report) in a report released on Thursday morning, Marketbeat Ratings reports. The firm issued a buy rating and a $12.

Bringing strengths in strategy, immuno-oncology science execution from bench to approval, major partnerships and collaborations, and biotech scale up To support the acceleration of proof-of-concept ...

Basilea will seek approval of ceftobiprole for SAB as well as acute bacterial skin ... fiscal year - with the bulk coming from antifungal therapy Cresemba (isavuconazole). There are nearly 120,000 ...

Zevtera is also the first new antibiotic for SAB to be approved by the FDA in ... in sales of Zevtera and antifungal therapy Cresemba (isavuconazole), with the latter drug accounting for the ...

The Immortal Monkey God Who Walks Among Us In the chaotic whirlwind of the modern world, where skyscrapers pierce the heavens ...

Ernexa Therapeutics . The new name reflects the company’s laser-focused mission and ambitious vision. “Eterna Therapeut ...

Dec. 10, 2024 — In a single IV injection, a gene therapy targeting cBIN1 can reverse the effects of heart failure and restore heart function in a large animal model. The therapy increases the ...

SAB's 2024 profit rises 15% to SAR 8.1B; Q4 at SAR 2.1B 12 M 2024 SAB’s 9M 2024 net profit rises 16% to SAR 5.9B; Q3 at SAR 1.9B 9 M 2024 SAB net profit rises 23% to SAR 4.06B in H1 2024; Q2 at SAR ...